Gland Pharma (NSE:GLAND) EBITDA Margin % : 26.07% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gland Pharma's EBITDA for the three months ended in Mar. 2024 was ₹4,008 Mil. Gland Pharma's Revenue for the three months ended in Mar. 2024 was ₹15,375 Mil. Therefore, Gland Pharma's EBITDA margin for the quarter that ended in Mar. 2024 was 26.07%.

Gland Pharma EBITDA Margin % Historical Data

The historical data trend for Gland Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma EBITDA Margin % Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBITDA Margin %

Get a 7-Day Free Trial

42.53

41.96

39.51

33.35

26.54

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															19.22	27.43	27.47	25.48	26.07

Competitive Comparison of Gland Pharma's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Gland Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gland Pharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Gland Pharma's EBITDA Margin % falls into.

Gland Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Gland Pharma's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	15033.08	/	56647.22
	=	26.54 %

Gland Pharma's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	4007.97	/	15374.5
	=	26.07 %

Gland Pharma (NSE:GLAND) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Gland Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Gland Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines